23andMe (NASDAQ:ME) Given “Sell (E+)” Rating at Weiss Ratings

23andMe (NASDAQ:ME)‘s stock had its “sell (e+)” rating reaffirmed by Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

23andMe Stock Performance

NASDAQ:ME remained flat at $3.61 on Friday. 475,228 shares of the company’s stock were exchanged, compared to its average volume of 194,032. The stock’s 50-day moving average price is $3.51 and its 200-day moving average price is $5.65. The company has a market cap of $94.29 million, a PE ratio of -0.14 and a beta of 1.14. 23andMe has a one year low of $2.65 and a one year high of $16.52.

23andMe (NASDAQ:ME) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) EPS for the quarter. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%. The business had revenue of $44.07 million during the quarter, compared to analysts’ expectations of $50.30 million.

Institutional Trading of 23andMe

Several institutional investors and hedge funds have recently bought and sold shares of ME. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of 23andMe in the 2nd quarter valued at approximately $203,000. Geode Capital Management LLC boosted its holdings in 23andMe by 0.7% in the third quarter. Geode Capital Management LLC now owns 4,246,093 shares of the company’s stock worth $1,476,000 after purchasing an additional 28,252 shares during the period. Point72 DIFC Ltd bought a new stake in 23andMe during the second quarter valued at $43,000. Vanguard Personalized Indexing Management LLC raised its holdings in shares of 23andMe by 410.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock worth $35,000 after purchasing an additional 71,204 shares during the period. Finally, FNY Investment Advisers LLC bought a new position in shares of 23andMe in the 4th quarter worth about $26,000. Institutional investors and hedge funds own 36.10% of the company’s stock.

23andMe Company Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.